Maravai LifeSciences
MRVI
235 hedge funds and large institutions have $4.51B invested in Maravai LifeSciences in 2022 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 80 increasing their positions, 79 reducing their positions, and 45 closing their positions.
348% more call options, than puts
Call options by funds: $14M | Put options by funds: $3.13M
18% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 45
3% more funds holding
Funds holding: 229 → 235 (+6)
1% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 79
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.13% less ownership
Funds ownership: 97.44% → 97.31% (-0.13%)
16% less capital invested
Capital invested by funds: $5.36B → $4.51B (-$852M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nekton Capital
London,
United Kingdom
|
+$37.2M |
| 2 |
N
Natixis
Paris,
France
|
+$33.5M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$32.3M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$29.4M |
| 5 |
OCBV
Ownership Capital B.V.
Amsterdam,
Netherlands
|
+$25.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$110M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$59.7M |
| 3 |
Select Equity Group
New York
|
-$48.4M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$35.7M |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$16.5M |
MRVI Hedge Fund Activity: Q1 2022 in Review
235 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q1 2022, worth a combined $4.51B — down 16% from $5.36B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new MRVI positions and 45 closed out — a net gain of 8 holders — while 80 added to existing stakes and 79 trimmed.
The largest buyer was Nekton Capital, opening a new position worth an estimated $37.2M. The largest seller was Fidelity Investments, cutting an estimated $110M.
- 235 institutional investors held Maravai LifeSciences (MRVI) as of Q1 2022, up from 229 in Q4 2021.
- Funds reported $4.51B of Maravai LifeSciences stock for Q1 2022, down 16% quarter-over-quarter.
- 53 funds opened new Maravai LifeSciences positions in Q1 2022 and 45 closed out, a net change of +8 holders.
- The largest Maravai LifeSciences buyer in Q1 2022 was Nekton Capital, an estimated $37.2M added.
- The largest Maravai LifeSciences seller in Q1 2022 was Fidelity Investments, an estimated $110M sold.
Based on aggregated 13F filings for Q1 2022.